S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$0.28
-17.8%
$4.79
$4.86
$37.50
$1.68M1.55467,323 shs867,643 shs
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
$0.00
$0.00
$0.00
N/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
$0.00
$2.91
$82.80
$1.90M2.031,362 shs6,500 shs
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$0.00
$0.00
$0.00
$0.11
$2K0.083,448 shs152 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-9.02%-12.87%-18.17%-21.44%-91.69%
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
0.00%0.00%0.00%0.00%-99.93%
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.00%0.00%0.00%0.00%0.00%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
-33.33%-33.33%0.00%0.00%-99.62%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$5.51M0.30N/AN/A$12.79 per share0.02
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
$610K0.00N/A0.08$341.84 per share0.00
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$6.43M0.00N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-$18.11M-$279.28N/AN/AN/A-254.26%-173.61%-131.01%N/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/A0.00N/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
-$81.15MN/A0.00N/AN/A-668.58%-163.22%-52.10%N/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
-$22.03MN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/A
6.87
5.97
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.05
1.17
1.07
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
65.06%
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/A

Insider Ownership

CompanyInsider Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
0.60%
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
61.19%
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
5.73%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Nuwellis, Inc. stock logo
CHFS
Nuwellis
666.04 millionN/ANot Optionable
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
62N/AN/ANot Optionable
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
43354,000N/ANot Optionable
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
4710.72 million10.11 millionNot Optionable

VIVE, RSLSD, CHFS, and NXNN Headlines

SourceHeadline
5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 20285-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028
finance.yahoo.com - April 17 at 6:28 PM
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
finance.yahoo.com - April 15 at 7:58 AM
Viveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 10:31 AM
The Best Medical Billing Services of 2024The Best Medical Billing Services of 2024
business.com - January 19 at 10:31 PM
VIVE Viveve Medical, Inc.VIVE Viveve Medical, Inc.
seekingalpha.com - July 29 at 9:53 AM
InMode Expands Womens Health and Wellness Market Footprint through Acquisition of Viveve PatentsInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents
finance.yahoo.com - July 25 at 9:01 AM
VIVE - Viveve Medical, Inc.VIVE - Viveve Medical, Inc.
uk.finance.yahoo.com - June 14 at 7:59 PM
Viveve Medical, Inc. (VIVE)Viveve Medical, Inc. (VIVE)
finance.yahoo.com - February 24 at 8:19 AM
Viveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinenceViveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinence
pharmabiz.com - January 20 at 9:26 AM
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesdays Mid-Day SessionWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
msn.com - January 17 at 3:40 PM
Viveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finanznachrichten.de - January 17 at 10:39 AM
Viveve crashes ~60% as company decides to delist, explore sale after trial failsViveve crashes ~60% as company decides to delist, explore sale after trial fails
seekingalpha.com - January 17 at 10:39 AM
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finance.yahoo.com - January 17 at 10:39 AM
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial
finance.yahoo.com - January 17 at 10:39 AM
Why Is Viveve Medical (VIVE) Stock Down 69% Today?Why Is Viveve Medical (VIVE) Stock Down 69% Today?
investorplace.com - January 17 at 10:03 AM
Viveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call Transcript
insidermonkey.com - December 29 at 9:56 AM
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
finance.yahoo.com - December 15 at 10:21 AM
Viveve gets US patent for treating female stress urinary incontinenceViveve gets US patent for treating female stress urinary incontinence
pharmabiz.com - December 3 at 7:46 AM
Viveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finanznachrichten.de - December 1 at 12:46 PM
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finance.yahoo.com - December 1 at 12:46 PM
Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - November 13 at 7:01 PM
InvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate UpdateInvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate Update
markets.buffalonews.com - November 12 at 7:52 AM
Viveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finanznachrichten.de - November 10 at 4:16 PM
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 4:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuwellis logo

Nuwellis

NASDAQ:CHFS
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Nexeon Medsystems logo

Nexeon Medsystems

OTCMKTS:NXNN
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
ReShape Lifesciences logo

ReShape Lifesciences

OTCMKTS:RSLSD
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
Viveve Medical logo

Viveve Medical

NASDAQ:VIVE
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.